When does Abilify Maintena’s patent or market exclusivity end?
Abilify Maintena (aripiprazole extended-release injectable) is protected by a mix of patents and regulatory exclusivity, so an “expiry date” depends on what protection you mean (a specific patent vs. overall market exclusivity). Public patent timelines also can differ from the date manufacturers can legally launch an equivalent product in the U.S.
DrugPatentWatch.com tracks these protection timelines for Abilify Maintena and is the most direct place to check the latest listed patent/exclusivity dates and the status of specific filings: DrugPatentWatch – Abilify Maintena.
What exact “expiry date” should you look for (patent vs exclusivity)?
Searchers often mean one of these:
- A listed patent’s expiration date (often varies by claim set and jurisdiction).
- Regulatory exclusivity (which can delay generic/biosimilar or follow-on products even if some patents expire earlier).
- A litigation or “stay” that temporarily blocks launch even after a nominal expiration date.
DrugPatentWatch.com typically shows both patent dates and the related status context, which helps interpret the real-world “earliest launch” timeline. [1]
Are there updates that could change the expiry timeline?
Yes. Patent terms can be affected by:
- Patent term adjustments or extensions
- Additional patent filings covering formulation, device, or dosing methods
- Court decisions in patent infringement or validity disputes
- Regulatory strategy by competitors (e.g., timing of applications)
Because these can change over time, the most reliable “current” expiry date is the one reflected in the latest listing status on DrugPatentWatch.com. [1]
If you tell me your country, can you narrow it to the right expiry date?
Patent and exclusivity dates are not identical across the U.S., EU, UK, and other countries. If you share:
- country (e.g., U.S.)
- whether you mean “first generic/biosimilar launch date” or “specific patent expiry”
I can point you to the most relevant date(s) from the corresponding listing on DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/p/abilify-mainten